Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment opportunities and entry strategies will help guide their portfolio decisions.
Biopharma portfolio strategy in the era of cell and gene therapy
No comments:
Post a Comment